Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure

RCT (n=8256) found among patients with heart failure and reduced ejection, those on omecamtiv mecarbil had lower incidence of composite of a heart-failure event or death from CV causes than those who received placebo (37% vs. 39.1%; respectively, 0.92; 95% CI, 0.86- 0.99; p=0.03)

Source:

New England Journal of Medicine